Embecta Corp
Research Embecta Corp (EMBC) on Bullrun: valuation model: 216.0% undervalued, market cap USD 196.37M, P/E 1.7, dividend yield 13.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEMBC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Valuation signal216.0% undervalued
- Market capUSD 196.37M
- P/E1.7
- Dividend yield13.9%
- Financial periodFY2025
- RevenueUSD 1.08B
- Revenue growth-3.8%
- Net incomeUSD 95.40M
- Free cash flowUSD 182.40M
- Gross margin62.6%
Valuation Snapshot
Bullrun's latest valuation model marks Embecta Corp as 216.0% undervalued; latest market cap is USD 196.37M; P/E is 1.7; dividend yield is 13.9%.
About Embecta Corp
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp.
Frequently asked questions
Is Embecta Corp overvalued or undervalued?
Bullrun's valuation model currently marks Embecta Corp as 216.0% undervalued.
What is Embecta Corp's market cap?
Embecta Corp's market capitalization is USD 196.37M.
What is Embecta Corp's P/E ratio?
Embecta Corp's price-to-earnings (P/E) ratio is 1.7.
Does Embecta Corp pay a dividend?
Embecta Corp has a dividend yield of 13.9%.
What does Embecta Corp do?
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally.